Acción NTII NEUROBIOLOGICAL TECHNOLOGIES, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Neurobiological Technologies, Inc.

Acciones

NTII

US64124W3043

Diferido OTC Markets
Otros sitios de cotización
 20:29:56 17/04/2024 		Varia. Cinco días. Varia. 1 de enero.
0,000001 USD -.--% Gráfico intradía de Neurobiological Technologies, Inc. -.--% -.--%

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Neurobiological Technologies Inc. Announces Extraordinary Dividend, Payable on December 27, 2012
NEUROBIO TECH : Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
NEUROBIO TECH : Neurobiological Technologies Announces Stockholder Approval of Plan of Liquidation and Dissolution
NEUROBIO TECH : Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
NEUROBIO TECH : Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
NEUROBIO TECH : Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Children's Medical Center
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Suspension of Viprinex Development
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
NEUROBIOLO TCHNLGS : Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
NEUROBIOLO TCHNLGS : Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
NEUROBIOLO TCHNLGS : Neurobiological Technologies Sets Date for First Quarter Financial Results
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
NEUROBIOLO TCHNLGS : Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción NTII
  4. Noticias Neurobiological Technologies, Inc.
  5. Otros idiomas